Which company developed the GLP-1 drug semaglutide under the brand name Ozempic?

Novo Nordisk developed the GLP-1 drug semaglutide under the brand name Ozempic.

Novo Nordisk is a Danish pharmaceutical company best known for diabetes and obesity treatments. It traces its history to the 1920s, when two Danish insulin businesses were established and later combined. The company has remained strongly focused on metabolic diseases.

Ozempic is the brand name for injectable semaglutide used to improve blood-sugar control in adults with type 2 diabetes. The same active ingredient is marketed under other brand names for different indications, including Wegovy for chronic weight management. Semaglutide belongs to the GLP-1 receptor agonist class, which imitates a naturally occurring hormone involved in blood glucose and appetite regulation.

A common mix-up is attributing Ozempic to Eli Lilly, whose competing medicines include dulaglutide and tirzepatide products. Demand for Novo Nordisk’s medicines helped make the company one of Europe’s most valuable listed businesses by market capitalization.